Zevra Therapeutics, Inc.
NASDAQZevra Therapeutics heads into September with a striking divergence: short sellers have spent a month covering positions aggressively, while institutional investors are quietly building some of the largest stakes the register has seen. The short covering story is the most compelling data point this week. Short interest has fallen roughly 22% over the past month, dropping from above…
ZVRA short interest surges 25.7% in one week to 11.0% of float, driven by stock rallying 23% amid analyst upgrade wave.
Snapshot as of 20 Sept 2026
Zevra Therapeutics heads into September with a striking divergence: short sellers have spent a month covering positions aggressively, while institutional investors are quietly building some of the largest stakes the…
Zevra Therapeutics is caught in an unusual tug-of-war this week: a stock up 26% over five days is simultaneously attracting a coordinated wave of analyst upgrades and a sharp build in short interest — two signals that…
Zevra Therapeutics heads into the post-earnings stretch with a clean beat under its belt and shorts sitting at a meaningful but steady 8.5% of the float. Q1 2026 results, reported after the close on May 6, came in well…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ZVRA — free to start on ORTEX.
Sign up for free →Open ZVRA on ORTEX